American Society of Hirudotherapy

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite

Review published in J Cardiothorac Vasc Anesth (2020)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentClinical TrialsGoswami D et al. · Journal of cardiothoracic and vascular anesthesia, 2020

Abstract

Anticoagulation is an essential component for patients undergoing cardiopulmonary bypass or extracorporeal membrane oxygenation and for those with ventricular assist devices. However, thrombosis and bleeding are common complications. Heparin continues to be the agent of choice for most patients, likely owing to practitioners' comfort and experience and the ease with which the drug's effects can be reversed. However, especially in pediatric cardiac surgery, there is increasing interest in using bivalirudin as the primary anticoagulant. This drug circumvents certain problems with heparin administration, such as heparin resistance and heparin-induced thrombocytopenia, but it comes with additional challenges. In this manuscript, the authors review the literature on the emerging role of bivalirudin in pediatric cardiac surgery, including its use with cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology. Moreover, they provide an overview of bivalirudin's pharmacodynamics and monitoring methods.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiac Surgical ProceduresCardiologyCardiopulmonary BypassChildHeparinHirudinsHumansPeptide FragmentsRecombinant Proteins

Summary

Review of bivalirudin pharmacodynamics and use in pediatric cardiac surgery including CPB, ECMO, VAD and interventional cardiology, particularly for heparin resistance and HIT.

Why This Matters for Hirudotherapy

This review examines the emerging role of bivalirudin as an alternative anticoagulant in pediatric cardiac surgery, including its use with cardiopulmonary bypass, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology. The authors survey the literature on bivalirudin's pharmacodynamics, monitoring methods, and its ability to circumvent heparin-associated problems such as heparin resistance and heparin-induced thrombocytopenia. The abstract does not mention hirudin, leeches, or any connection to the leech secretome, so no defensible hirudotherapy link can be drawn from this article. This is a review article without original clinical data, and it does not involve leeches or hirudotherapy.

Citation

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.

Goswami D et al. · Journal of cardiothoracic and vascular anesthesia, 2020

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.